Q4 2024 Tarsus Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Tarsus Pharmaceuticals Inc (TARS) reported over $180 million in net product sales for 2024, exceeding expectations.
- The company expanded its sales force from 100 to 150 representatives, increasing its reach to over 15,000 eye care physicians.
- XDEMVY, Tarsus Pharmaceuticals Inc (TARS)'s product, now has commercial and Medicare coverage extending to more than 90% of potential patient lives.
- The company launched a successful direct-to-consumer advertising campaign, expanding into major network TV events, which has increased patient engagement.
- Tarsus Pharmaceuticals Inc (TARS) is advancing its pipeline with a phase 2 trial for ocular rosacea and a Lyme disease prevention program, indicating strong future growth potential.
- Operating expenses for 2024 were high at approximately $303.5 million, primarily due to commercial and marketing costs.
- The gross-to-net discount is expected to be slightly higher in the first quarter of 2025, impacting revenue.
- The company anticipates typical sector dynamics and external factors like winter storms and natural disasters to affect first-quarter sales.
- There is uncertainty regarding the long-term impact and ROI of the direct-to-consumer campaign, which requires ongoing evaluation.
- The Lyme disease prevention program may require a larger partner for phase 3 trials due to the expected size and cost of the study.
Good morning and welcome to Tarsus this year in 2024 financial results conference call. As a reminder, this call is being recorded at this time.
I would like to turn the call over to David Nakasone, Head of Investor Relations, to lead off the call. David, you may begin.
Thank you. Before we begin, I encourage everyone to go to the investors section of the Tarsus website to view the earnings release and related materials we will be discussing today.
Joining me on the call this morning are Bobby Azamian, our Chief Executive Officer and Chairman, Aziz Mottiwala, our Chief Commercial Officer, Sesha Neervannan, our Chief Operating Officer, and Jeff Farrow, our Chief Financial Officer and Chief Strategy Officer.
I'd like to draw your attention to slide 3, which contains our forward-looking statements. During this call, we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
